Industries > Pharma > Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023

Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023

PUBLISHED: 01 July 2013
PAGES: 217
PRODUCT CODE:

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE

Contract manufacturing for pharma – discover top companies' revenue prospects

How are pharma contract manufacturing organisations (CMOs) performing? Visiongain's new report shows you their prospects to 2023. There you see results, trends, opportunities, and revenue predictions.

Our study analyses 30 leading CMOs. There you discover how revenues from drug production services can increase.

That way you find information you need on established and emerging companies. Read on to scan those organisations and see what their future market could be worth.

Forecasts and other data to help you stay ahead

In our new study you find analytical profiles of 30 top companies, and analyses of the overall industry. You discover historical data, market shares, revenue forecasts, and growth rates. See, too, qualitative analysis, business outlooks and developments.

There you also gain 141 tables, 58 charts, and five interviews with the industry.

Our work lets you assess the most lucrative services in outsourced drug making. That way you can stay ahead in knowledge of the CMO industry and market:
• Finished dosage formulations (FDF) manufacturing
• Active pharmaceutical ingredients (API) production.

See now how you can benefit your research, analyses and decisions, also saving time. The following sections highlight what you find in our new investigation.

Company profiles – activities, results, competition, and prospects

Our report analyses 30 leading companies. The content of each profile differs, depending on the company. In general, though, a profile gives you the following information:
• Overview of the company's contract manufacturing services, including clients
• Analysis of recent financial performance – overall revenue and that for CMO services
• Assessment of developments – acquisitions, capacity expansions, new service offerings, and collaborations
• SWOT analysis of the company – strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2013 to 2023
• Forecasting of pharmaceutical contract manufacturing revenues to 2023, for 23 of the companies
• Transcript of an interview by Visiongain, for five of the companies.

Discover there what participants achieve, do, and say, helping you stay ahead.

European contract manufacturing organisations

First, our study gives you discussions, financial analyses, and commercial outlooks for 15 European CMOs, including these:
• Lonza
• Evonik Degussa
• Royal DSM
• Boehringer Ingelheim Biopharmaceuticals
• Famar
• Fareva
• Vetter Pharma.

Discover what the future holds for those pharma service providers, including revenue outlooks to 2023.

Companies based in the US and Japan

Next, our report shows you developments and sales outlooks to 2023 for five other companies:
• Catalent Pharma Solutions
• Patheon
• AbbVie Contract Manufacturing
• Daito Pharmaceutical
• Pfizer CentreSource.

Our work shows you where sales growth can occur. Many opportunities remain, with high, expanding revenues possible from 2013. You see where prospects exist.

Developed-market API specialists

You also discover outlooks for four top producers of active pharma ingredients:
• Teva API
• Esteve Química
• Euticals
• Cambrex.

Our report shows you potentials of the industry. You see possibilities for advancing technology and raising business performance.

India and China – analysis of pharma manufacturing service providers

Our work also assesses six Indian and Chinese companies. There you discover activities and prospects of these firms:
• Dr. Reddy's Laboratories
• Aurobindo Pharma
• Divis Laboratories
• Shandong Xinhua Pharmaceutical
• Zhejiang Hisun Pharmaceutical
• Zhejiang Huahai Pharmaceuticals.

That way you find sales data and underlying trends, seeing what the present and future hold.

Predictions for the worldwide pharma CMO market and submarkets

Our report also forecasts revenues to 2023 for the world contract manufacturing industry and its main segments: APIs and FDFs.

There you see overall world revenues in 2017 reaching $66.4bn. Our analyses reveal high growth from 2013 to 2023. That work also predicts large companies and specialty healthcare firms will develop and prosper. She how and where, finding potential.

Biologics and biosimilars also hold promise. New biological therapies – including antibody-drug conjugates and regenerative medicines – interest CMOs and clients.

Discover opportunities and revenue predictions, then, for outsourced production of medicines. You investigate established and rising companies, finding their prospects.

Six ways Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023 helps you

In particular, our new investigation gives you the following knowledge:
• Revenues to 2023 for the world CMO market and its components – discover that industry's prospects, finding promising places for investments and revenues
• Profiles of 30 leading companies – assess services, strategies, sales results and outlooks, also gaining revenue forecasts to 2023 for 23 of the organisations
• Interviews with 5 companies in the CMO industry – discover debates and opinions to help you stay ahead
• Competition and opportunities – see what affects that industry, learning what shapes its future, esp. prospects for sustaining and developing business
• Analysis of what stimulates and restrains that industry and market – assess challenges and strengths, helping you compete and gain advantages
• Outlooks for established players and firms entering the sector – explore needs, practices, and outlooks for future success.

Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our new survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Prospects for pharma manufacturing providers – gain by ordering now

Our study lets you find data, trends, opportunities, and commercial predictions for outsourced drug and API production. Avoid missing out – please order our new report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

To view free sample pages of this report please click here

Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023


Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023


Latest Pharma news

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

READ

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

READ

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

READ

“Global Rare Disease Drugs market set to grow to $257bn by 2024” says new Visiongain report

It is difficult to investigate rare diseases as the pool of patients is very small and often results in inadequate clinical knowledge.

01 August 2019

READ

Categories

Category